CL2020003438A1 - Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas (divisional de la solicitud no. 201903843) - Google Patents

Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas (divisional de la solicitud no. 201903843)

Info

Publication number
CL2020003438A1
CL2020003438A1 CL2020003438A CL2020003438A CL2020003438A1 CL 2020003438 A1 CL2020003438 A1 CL 2020003438A1 CL 2020003438 A CL2020003438 A CL 2020003438A CL 2020003438 A CL2020003438 A CL 2020003438A CL 2020003438 A1 CL2020003438 A1 CL 2020003438A1
Authority
CL
Chile
Prior art keywords
recombinant viral
human cells
genetic material
divisional application
viral particles
Prior art date
Application number
CL2020003438A
Other languages
English (en)
Inventor
Andrew J Murphy
Christos Kyratsous
Christopher Schoenherr
Leah Sabin
Aris N Economides
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63080488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020003438(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2020003438A1 publication Critical patent/CL2020003438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente descripción se proporcionan composiciones y métodos para reorientar partículas de cápsidas virales recombinantes a través de un par de unión proteína:proteína específico que forma un enlace covalente, por ejemplo, isopeptídico, para mostrar un ligando de orientación sobre la proteína de cápsida, en donde el ligando de orientación se une específicamente a un marcador de superficie celular expresado en la célula de interés.
CL2020003438A 2017-06-27 2020-12-30 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas (divisional de la solicitud no. 201903843) CL2020003438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762525708P 2017-06-27 2017-06-27

Publications (1)

Publication Number Publication Date
CL2020003438A1 true CL2020003438A1 (es) 2021-07-23

Family

ID=63080488

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2019003843A CL2019003843A1 (es) 2017-06-27 2019-12-26 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas.
CL2020003438A CL2020003438A1 (es) 2017-06-27 2020-12-30 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas (divisional de la solicitud no. 201903843)
CL2025002293A CL2025002293A1 (es) 2017-06-27 2025-08-01 Partículas virales recombinantes con tropismo modificado y sus usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019003843A CL2019003843A1 (es) 2017-06-27 2019-12-26 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2025002293A CL2025002293A1 (es) 2017-06-27 2025-08-01 Partículas virales recombinantes con tropismo modificado y sus usos

Country Status (30)

Country Link
US (1) US20200140492A1 (es)
EP (4) EP4706687A3 (es)
JP (5) JP2020525020A (es)
KR (3) KR20200021987A (es)
CN (2) CN116891534A (es)
AU (4) AU2018290885B2 (es)
BR (1) BR112019027866A2 (es)
CA (1) CA3066950A1 (es)
CL (3) CL2019003843A1 (es)
CO (1) CO2019014684A2 (es)
CY (1) CY1126149T1 (es)
DK (1) DK3645553T5 (es)
ES (1) ES2943020T3 (es)
FI (1) FI3645553T3 (es)
HR (1) HRP20230538T1 (es)
HU (1) HUE061908T2 (es)
IL (2) IL318395A (es)
LT (1) LT3645553T (es)
MA (1) MA49514B1 (es)
MD (1) MD3645553T2 (es)
MX (2) MX2020000246A (es)
PE (2) PE20251541A1 (es)
PH (1) PH12019550269B1 (es)
PL (1) PL3645553T3 (es)
PT (1) PT3645553T (es)
RS (1) RS64233B1 (es)
SG (1) SG11201911614XA (es)
SI (1) SI3645553T1 (es)
SM (1) SMT202300168T1 (es)
WO (1) WO2019006046A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US12421525B2 (en) 2018-02-28 2025-09-23 University of Pittsburgh—of the Commonwealth System of Higher Education Conjugates comprising AAVs and CAS9 polypeptides
EP3774926A1 (en) 2018-04-05 2021-02-17 Bio-Rad ABD Serotec GmbH Display systems for proteins of interest
GB201903479D0 (en) * 2019-03-14 2019-05-01 Univ Oxford Innovation Ltd Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof
CN113874518B (zh) * 2019-03-18 2025-04-25 生物辐射Abd瑟罗泰克有限公司 保护含SpyTag的周质融合蛋白免于蛋白酶Tsp和OmpT降解
AU2020283537A1 (en) * 2019-05-24 2021-12-16 Regeneron Pharmaceuticals, Inc. Modified viral particles and uses thereof
US12215288B2 (en) * 2019-06-11 2025-02-04 Chevron U.S.A. Inc. Membranes for contaminant removal from natural gas and methods for use thereof
BR112021026309A2 (pt) * 2019-06-26 2022-06-07 Ap Biosciences Inc Anticorpos para ativação de células t
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
EP4055030A4 (en) 2019-11-08 2024-05-22 President And Fellows Of Harvard College VIRAL CAPSID POLYPEPTIDES
EP4055034A4 (en) 2019-11-08 2024-05-29 President And Fellows Of Harvard College VIRAL CAPSID POLYPEPTIDES
CN114632148B (zh) * 2020-12-15 2024-08-09 榕森生物科技(北京)有限公司 病原样抗原疫苗及其制备方法
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
MX2024005314A (es) 2021-11-04 2024-05-17 Regeneron Pharma Particulas virales redirigidas a musculo esqueletico.
CN114213505B (zh) * 2021-12-10 2022-09-20 和元生物技术（上海）股份有限公司 一种适用于特异感染u87-mg细胞的腺相关病毒突变体
US12584145B2 (en) 2022-04-15 2026-03-24 Washington University Conjugate systems and methods of use thereof
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
MA71631A (fr) 2022-07-29 2025-05-30 Regeneron Pharmaceuticals, Inc. Particules virales reciblées vers le récepteur 1 de transferrine
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
US20240168018A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and evaluating viruses and virus-like particles
WO2024124019A2 (en) * 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
CN115819628B (zh) * 2022-12-28 2026-07-28 河南赛诺特生物技术有限公司 一种高免疫原性与反应性的cd47膜蛋白及其制备方法和应用
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
WO2024263705A2 (en) 2023-06-20 2024-12-26 Regeneron Pharmaceuticals, Inc. Methods for purifying filled adeno-associated virus capsids
JPWO2025018388A1 (es) * 2023-07-20 2025-01-23
CN119552829A (zh) * 2023-09-01 2025-03-04 北京昌平实验室 靶向性基因编辑酶工程化的腺相关病毒及其药物组合物
CN121794393A (zh) 2023-09-07 2026-04-03 里珍纳龙药品有限公司 经共价表面修饰的腺相关病毒的生产和纯化
WO2025084336A1 (ja) 2023-10-17 2025-04-24 国立大学法人大阪大学 Ａａｖのキャプシドと標的受容体に同時に結合することができる分子
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
AU2025207849A1 (en) 2024-01-11 2026-07-16 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025155923A1 (en) 2024-01-17 2025-07-24 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025217174A1 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
WO2025217163A2 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Novel aav capsids binding to human cd59
WO2026025058A1 (en) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Aav viral particles retargeted to egfr-expressing cancer cells
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof
WO2026050618A1 (en) 2024-08-29 2026-03-05 Regeneron Pharmaceuticals, Inc. Polynucleotide constructs and cell lines for recombinant aav production
WO2026112457A2 (en) 2024-11-21 2026-05-28 Regeneron Pharmaceuticals, Inc. Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof
CN119529113A (zh) * 2024-11-28 2025-02-28 浙江大学 一种基于PCV2 VLPs的纳米抗原展示平台及制备方法和应用
CN120519522B (zh) * 2025-07-23 2025-11-18 南昌大学第一附属医院 基于双向负载模块的通用工程外泌体构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286981C (zh) * 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
WO2011072204A1 (en) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US20160018835A1 (en) * 2014-07-18 2016-01-21 Retroficiency, Inc. System and method for virtual energy assessment of facilities
AU2016207099C1 (en) * 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
CN107438625A (zh) 2015-02-26 2017-12-05 Var2制药有限公司 使用嵌合抗原受体（cars）的胎盘样硫酸软骨素的免疫治疗靶向和使用具有分割蛋白结合系统的cars的癌症的免疫治疗靶向
EP3141600A1 (en) 2015-09-11 2017-03-15 Institut National de la Recherche Agronomique Nepovirus coat protein fusion polypeptides and their use
CA3034089A1 (en) * 2016-08-18 2018-02-22 The Regents Of The University Of California Crispr-cas genome engineering via a modular aav delivery system
US12421525B2 (en) 2018-02-28 2025-09-23 University of Pittsburgh—of the Commonwealth System of Higher Education Conjugates comprising AAVs and CAS9 polypeptides

Also Published As

Publication number Publication date
CA3066950A1 (en) 2019-01-03
CO2019014684A2 (es) 2020-01-17
ES2943020T3 (es) 2023-06-08
EP4706687A3 (en) 2026-07-15
PT3645553T (pt) 2023-05-08
EP4706687A2 (en) 2026-03-11
MD3645553T2 (ro) 2023-07-31
CY1126149T1 (el) 2023-11-15
DK3645553T5 (da) 2024-08-26
PH12019550269B1 (en) 2024-05-22
AU2018290885A1 (en) 2020-01-16
SG11201911614XA (en) 2020-01-30
AU2023204611A1 (en) 2023-08-03
HUE061908T2 (hu) 2023-09-28
MX2020000246A (es) 2020-08-10
CL2019003843A1 (es) 2020-07-24
SMT202300168T1 (it) 2023-07-20
JP2024071769A (ja) 2024-05-24
JP2022186991A (ja) 2022-12-15
RU2020101596A (ru) 2021-07-27
PH12019550269A1 (en) 2021-01-11
JP2025129257A (ja) 2025-09-04
IL318395A (en) 2025-03-01
AU2018290885B2 (en) 2023-07-27
SI3645553T1 (sl) 2023-06-30
PE20251541A1 (es) 2025-06-05
IL271570B1 (en) 2026-01-01
JP2020525020A (ja) 2020-08-27
EP4706688A2 (en) 2026-03-11
MA49514A (fr) 2020-05-06
MA49514B1 (fr) 2023-06-28
US20200140492A1 (en) 2020-05-07
MX2023009051A (es) 2023-08-10
KR20200021987A (ko) 2020-03-02
CN116891534A (zh) 2023-10-17
EP4706688A3 (en) 2026-05-27
WO2019006046A2 (en) 2019-01-03
AU2026200716A1 (en) 2026-02-19
PE20200895A1 (es) 2020-09-08
CN110997699A (zh) 2020-04-10
RU2020101596A3 (es) 2022-03-22
DK3645553T3 (da) 2023-05-22
CL2025002293A1 (es) 2025-11-14
IL271570A (en) 2020-02-27
EP4219529A1 (en) 2023-08-02
BR112019027866A2 (pt) 2020-07-07
IL271570B2 (en) 2026-05-01
HRP20230538T1 (hr) 2023-08-04
LT3645553T (lt) 2023-04-25
KR20250091321A (ko) 2025-06-20
EP3645553A2 (en) 2020-05-06
PL3645553T3 (pl) 2023-07-17
RS64233B1 (sr) 2023-06-30
JP2026127663A (ja) 2026-08-06
AU2026200717A1 (en) 2026-02-19
KR20260039813A (ko) 2026-03-20
WO2019006046A3 (en) 2019-02-14
AU2023204611B2 (en) 2025-10-30
EP3645553B1 (en) 2023-03-15
FI3645553T3 (fi) 2023-05-22

Similar Documents

Publication Publication Date Title
CO2019014684A2 (es) Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas
CL2020003343A1 (es) Vectores virales recombinantes con tropismo modificado y usos de los mismos para la introducción dirigida de material genético a células humanas (divisional de la solicitud 201903842)
JOP20200307A1 (ar) جزيئات ربط ضد bcma واستخداماتها
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX378807B (es) Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
WO2014183071A3 (en) In vitro production of red blood cells with sortaggable proteins
MY196882A (en) Recombinant binding proteins and their use
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
NI201700001A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX2021001158A (es) Vector hsv oncolitico.
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
MX2019006633A (es) Formulaciones de anticuerpo.
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MX377080B (es) Construcciones de variantes de sirp-alfa y sus usos.
AU2016335217A8 (en) Antigen receptors and uses thereof
AR078716A1 (es) Anticuerpos antihepsina y metodos para su uso
CL2022003101A1 (es) Partículas virales recombinantes con tropismo modificado y sus usos (divisional de 201903843)
MX2016003302A (es) Metodo de transfeccion de la version soluble pro-apoptotica de la proteina especifica del arresto celular 1 (tgas1) en celulas de glioma mediante nanoparticulas de poliplex-neurotensina.
JO3545B1 (ar) تركيبات الناقل-الجسم المضاد وطرق صناعتها واستخدامها